Global Anti-infective Agents

Anti-infective Agents Comprehensive Study by Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Application (Hospital Use, Clinic Use, Household, Other), Drug Type (Penicillins, Sulfonamides, Antimycobacterial, Trimethoprim-Sulfamethoxazole, Aminoglycosides, Macrolides, Chloramphenicol, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online, Others), End-User (Children, Adults), Side Effects (Kidney Damage, GI Toxicity, Neurotoxicity, Hypersensitivity Reactions, Superinfections) Players and Region - Global Market Outlook to 2028

Anti-infective Agents Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Anti-infective Agents Market Scope?
Anti-infectives are drugs that are used to act on the body against invading foreign organisms, especially those that can cause infection. Anti-infectives act on invading organisms in a number of ways. Over time, invading pathogens develop resistance to anti-infectives. Resistance is the ability to adapt to an anti-infectious drug over time and produce cells that are no longer affected by a particular drug. Anti-infectives like metronidazole, clindamycin, tigecycline, linezolid, and vancomycin work against many types of bacteria that have become resistant to other antibiotics.

Influencing Trend:
Spreading Awareness amongst People Regarding the Fatal Implications of Infectious Diseases and the Importance of Early Treatment, Increased Prescription and Accessibility of Antibacterial Due To Their Over-The-Counter Status and Development of Combination Drugs to Treat and Prevent Serious and Life-Threatening Infections

Market Growth Drivers:
Rising Prevalence of Infectious Diseases Such As HIV, H1N1, and Ebola Virus, Increasing Awareness among Healthcare Professionals and Patients and Increased Potency and Efficacy and the Commercialization of Pipeline Products

Challenges:
Lack of Awareness in Underdeveloped Regions

Restraints:
Stringent Regulatory Framework Pertaining To the Usage of Drugs

Opportunities:
New Product Development and Presence of Strong Product Pipeline, An Increase in Funding From the Government for the Research Activities Pertaining To Discovery of the Drugs and Spread Awareness and To Enhance the Treatment of Communicable Diseases in Developing Countries

The Anti-infective Agents market study is being classified by Type (Antibacterial Drugs, Antifungal Drugs and Antiviral Drugs), by Application and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from European will contribute to the maximum growth of Global Anti-infective Agents market throughout the predicted period.

Pfizer Inc. (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Gilead Sciences, Inc. (United States), Bristol-Myers Squibb Co. (United States), Merck & Co., Inc. (United States), Bayer Healthcare AG (Germany), AstraZeneca Plc. (United Kingdom), Boehringer Ingelheim (Germany), Novartis AG (Switzerland), Astellas Pharma, Inc. (Japan) and GlaxoSmithKline Plc. (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Alcon Pharmaceuticals Ltd. (Switzerland) and Sanofi-Aventis S.A. (France).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Anti-infective Agents market by Type, Application and Region.

On the basis of geography, the market of Anti-infective Agents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).


The World Health Organization has identified antimicrobial resistance as one of the three greatest threats to human health. Unfortunately, many large pharmaceutical companies have discontinued their antibiotic discovery and development programs. With a marked decline in the discovery of new antimicrobials, the world is now facing an enormous and growing threat from the emergence of bacteria that are resistant to almost all available antibiotics. As stated by the Infectious Diseases Society of America in their 'Bad Bugs, No Drugs' paper: "As antibiotic discovery stagnates, a public health crisis brews." There is therefore an urgent need to discover novel antimicrobials and develop innovative strategies for better use of available antibiotics to combat the global antimicrobial resistance crisis.

Key Target Audience
Providers of Anti-infective Agents, End-Users, Potential Investors, Market Research Firms and Others

Anti-infective Agents Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Anti-infective Agents Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Anti-infective Agents industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Antibacterial Drugs
  • Antifungal Drugs
  • Antiviral Drugs
By Application
  • Hospital Use
  • Clinic Use
  • Household
  • Other
By Drug Type
  • Penicillins
  • Sulfonamides
  • Antimycobacterial
  • Trimethoprim-Sulfamethoxazole
  • Aminoglycosides
  • Macrolides
  • Chloramphenicol
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online
  • Others

By End-User
  • Children
  • Adults

By Side Effects
  • Kidney Damage
  • GI Toxicity
  • Neurotoxicity
  • Hypersensitivity Reactions
  • Superinfections

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Infectious Diseases Such As HIV, H1N1, and Ebola Virus
      • 3.2.2. Increasing Awareness among Healthcare Professionals and Patients
      • 3.2.3. Increased Potency and Efficacy and the Commercialization of Pipeline Products
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in Underdeveloped Regions
    • 3.4. Market Trends
      • 3.4.1. Spreading Awareness amongst People Regarding the Fatal Implications of Infectious Diseases and the Importance of Early Treatment
      • 3.4.2. Increased Prescription and Accessibility of Antibacterial Due To Their Over-The-Counter Status
      • 3.4.3. Development of Combination Drugs to Treat and Prevent Serious and Life-Threatening Infections
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-infective Agents, by Type, Application, Drug Type, Distribution Channel, End-User, Side Effects and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-infective Agents (Value)
      • 5.2.1. Global Anti-infective Agents by: Type (Value)
        • 5.2.1.1. Antibacterial Drugs
        • 5.2.1.2. Antifungal Drugs
        • 5.2.1.3. Antiviral Drugs
      • 5.2.2. Global Anti-infective Agents by: Application (Value)
        • 5.2.2.1. Hospital Use
        • 5.2.2.2. Clinic Use
        • 5.2.2.3. Household
        • 5.2.2.4. Other
      • 5.2.3. Global Anti-infective Agents by: Drug Type (Value)
        • 5.2.3.1. Penicillins
        • 5.2.3.2. Sulfonamides
        • 5.2.3.3. Antimycobacterial
        • 5.2.3.4. Trimethoprim-Sulfamethoxazole
        • 5.2.3.5. Aminoglycosides
        • 5.2.3.6. Macrolides
        • 5.2.3.7. Chloramphenicol
        • 5.2.3.8. Others
      • 5.2.4. Global Anti-infective Agents by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online
        • 5.2.4.4. Others
      • 5.2.5. Global Anti-infective Agents by: End-User (Value)
        • 5.2.5.1. Children
        • 5.2.5.2. Adults
      • 5.2.6. Global Anti-infective Agents by: Side Effects (Value)
        • 5.2.6.1. Kidney Damage
        • 5.2.6.2. GI Toxicity
        • 5.2.6.3. Neurotoxicity
        • 5.2.6.4. Hypersensitivity Reactions
        • 5.2.6.5. Superinfections
      • 5.2.7. Global Anti-infective Agents Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Anti-infective Agents (Volume)
      • 5.3.1. Global Anti-infective Agents by: Type (Volume)
        • 5.3.1.1. Antibacterial Drugs
        • 5.3.1.2. Antifungal Drugs
        • 5.3.1.3. Antiviral Drugs
      • 5.3.2. Global Anti-infective Agents by: Application (Volume)
        • 5.3.2.1. Hospital Use
        • 5.3.2.2. Clinic Use
        • 5.3.2.3. Household
        • 5.3.2.4. Other
      • 5.3.3. Global Anti-infective Agents by: Drug Type (Volume)
        • 5.3.3.1. Penicillins
        • 5.3.3.2. Sulfonamides
        • 5.3.3.3. Antimycobacterial
        • 5.3.3.4. Trimethoprim-Sulfamethoxazole
        • 5.3.3.5. Aminoglycosides
        • 5.3.3.6. Macrolides
        • 5.3.3.7. Chloramphenicol
        • 5.3.3.8. Others
      • 5.3.4. Global Anti-infective Agents by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online
        • 5.3.4.4. Others
      • 5.3.5. Global Anti-infective Agents by: End-User (Volume)
        • 5.3.5.1. Children
        • 5.3.5.2. Adults
      • 5.3.6. Global Anti-infective Agents by: Side Effects (Volume)
        • 5.3.6.1. Kidney Damage
        • 5.3.6.2. GI Toxicity
        • 5.3.6.3. Neurotoxicity
        • 5.3.6.4. Hypersensitivity Reactions
        • 5.3.6.5. Superinfections
      • 5.3.7. Global Anti-infective Agents Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Anti-infective Agents (Price)
      • 5.4.1. Global Anti-infective Agents by: Type (Price)
  • 6. Anti-infective Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gilead Sciences, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb Co. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer Healthcare AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca Plc. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Astellas Pharma, Inc. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Anti-infective Agents Sale, by Type, Application, Drug Type, Distribution Channel, End-User, Side Effects and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-infective Agents (Value)
      • 7.2.1. Global Anti-infective Agents by: Type (Value)
        • 7.2.1.1. Antibacterial Drugs
        • 7.2.1.2. Antifungal Drugs
        • 7.2.1.3. Antiviral Drugs
      • 7.2.2. Global Anti-infective Agents by: Application (Value)
        • 7.2.2.1. Hospital Use
        • 7.2.2.2. Clinic Use
        • 7.2.2.3. Household
        • 7.2.2.4. Other
      • 7.2.3. Global Anti-infective Agents by: Drug Type (Value)
        • 7.2.3.1. Penicillins
        • 7.2.3.2. Sulfonamides
        • 7.2.3.3. Antimycobacterial
        • 7.2.3.4. Trimethoprim-Sulfamethoxazole
        • 7.2.3.5. Aminoglycosides
        • 7.2.3.6. Macrolides
        • 7.2.3.7. Chloramphenicol
        • 7.2.3.8. Others
      • 7.2.4. Global Anti-infective Agents by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online
        • 7.2.4.4. Others
      • 7.2.5. Global Anti-infective Agents by: End-User (Value)
        • 7.2.5.1. Children
        • 7.2.5.2. Adults
      • 7.2.6. Global Anti-infective Agents by: Side Effects (Value)
        • 7.2.6.1. Kidney Damage
        • 7.2.6.2. GI Toxicity
        • 7.2.6.3. Neurotoxicity
        • 7.2.6.4. Hypersensitivity Reactions
        • 7.2.6.5. Superinfections
      • 7.2.7. Global Anti-infective Agents Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Anti-infective Agents (Volume)
      • 7.3.1. Global Anti-infective Agents by: Type (Volume)
        • 7.3.1.1. Antibacterial Drugs
        • 7.3.1.2. Antifungal Drugs
        • 7.3.1.3. Antiviral Drugs
      • 7.3.2. Global Anti-infective Agents by: Application (Volume)
        • 7.3.2.1. Hospital Use
        • 7.3.2.2. Clinic Use
        • 7.3.2.3. Household
        • 7.3.2.4. Other
      • 7.3.3. Global Anti-infective Agents by: Drug Type (Volume)
        • 7.3.3.1. Penicillins
        • 7.3.3.2. Sulfonamides
        • 7.3.3.3. Antimycobacterial
        • 7.3.3.4. Trimethoprim-Sulfamethoxazole
        • 7.3.3.5. Aminoglycosides
        • 7.3.3.6. Macrolides
        • 7.3.3.7. Chloramphenicol
        • 7.3.3.8. Others
      • 7.3.4. Global Anti-infective Agents by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online
        • 7.3.4.4. Others
      • 7.3.5. Global Anti-infective Agents by: End-User (Volume)
        • 7.3.5.1. Children
        • 7.3.5.2. Adults
      • 7.3.6. Global Anti-infective Agents by: Side Effects (Volume)
        • 7.3.6.1. Kidney Damage
        • 7.3.6.2. GI Toxicity
        • 7.3.6.3. Neurotoxicity
        • 7.3.6.4. Hypersensitivity Reactions
        • 7.3.6.5. Superinfections
      • 7.3.7. Global Anti-infective Agents Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Anti-infective Agents (Price)
      • 7.4.1. Global Anti-infective Agents by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-infective Agents: by Type(USD Million)
  • Table 2. Anti-infective Agents Antibacterial Drugs , by Region USD Million (2017-2022)
  • Table 3. Anti-infective Agents Antifungal Drugs , by Region USD Million (2017-2022)
  • Table 4. Anti-infective Agents Antiviral Drugs , by Region USD Million (2017-2022)
  • Table 5. Anti-infective Agents: by Application(USD Million)
  • Table 6. Anti-infective Agents Hospital Use , by Region USD Million (2017-2022)
  • Table 7. Anti-infective Agents Clinic Use , by Region USD Million (2017-2022)
  • Table 8. Anti-infective Agents Household , by Region USD Million (2017-2022)
  • Table 9. Anti-infective Agents Other , by Region USD Million (2017-2022)
  • Table 10. Anti-infective Agents: by Drug Type(USD Million)
  • Table 11. Anti-infective Agents Penicillins , by Region USD Million (2017-2022)
  • Table 12. Anti-infective Agents Sulfonamides , by Region USD Million (2017-2022)
  • Table 13. Anti-infective Agents Antimycobacterial , by Region USD Million (2017-2022)
  • Table 14. Anti-infective Agents Trimethoprim-Sulfamethoxazole , by Region USD Million (2017-2022)
  • Table 15. Anti-infective Agents Aminoglycosides , by Region USD Million (2017-2022)
  • Table 16. Anti-infective Agents Macrolides , by Region USD Million (2017-2022)
  • Table 17. Anti-infective Agents Chloramphenicol , by Region USD Million (2017-2022)
  • Table 18. Anti-infective Agents Others , by Region USD Million (2017-2022)
  • Table 19. Anti-infective Agents: by Distribution Channel(USD Million)
  • Table 20. Anti-infective Agents Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 21. Anti-infective Agents Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 22. Anti-infective Agents Online , by Region USD Million (2017-2022)
  • Table 23. Anti-infective Agents Others , by Region USD Million (2017-2022)
  • Table 24. Anti-infective Agents: by End-User(USD Million)
  • Table 25. Anti-infective Agents Children , by Region USD Million (2017-2022)
  • Table 26. Anti-infective Agents Adults , by Region USD Million (2017-2022)
  • Table 27. Anti-infective Agents: by Side Effects(USD Million)
  • Table 28. Anti-infective Agents Kidney Damage , by Region USD Million (2017-2022)
  • Table 29. Anti-infective Agents GI Toxicity , by Region USD Million (2017-2022)
  • Table 30. Anti-infective Agents Neurotoxicity , by Region USD Million (2017-2022)
  • Table 31. Anti-infective Agents Hypersensitivity Reactions , by Region USD Million (2017-2022)
  • Table 32. Anti-infective Agents Superinfections , by Region USD Million (2017-2022)
  • Table 33. South America Anti-infective Agents, by Country USD Million (2017-2022)
  • Table 34. South America Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 35. South America Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 36. South America Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 37. South America Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 38. South America Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 39. South America Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 40. Brazil Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 41. Brazil Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 42. Brazil Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 43. Brazil Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 44. Brazil Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 45. Brazil Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 46. Argentina Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 47. Argentina Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 48. Argentina Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 49. Argentina Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 50. Argentina Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 51. Argentina Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 52. Rest of South America Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 53. Rest of South America Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 54. Rest of South America Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 55. Rest of South America Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 56. Rest of South America Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 57. Rest of South America Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 58. Asia Pacific Anti-infective Agents, by Country USD Million (2017-2022)
  • Table 59. Asia Pacific Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 60. Asia Pacific Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 61. Asia Pacific Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 62. Asia Pacific Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 63. Asia Pacific Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 64. Asia Pacific Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 65. China Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 66. China Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 67. China Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 68. China Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 69. China Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 70. China Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 71. Japan Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 72. Japan Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 73. Japan Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 74. Japan Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 75. Japan Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 76. Japan Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 77. India Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 78. India Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 79. India Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 80. India Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 81. India Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 82. India Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 83. South Korea Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 84. South Korea Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 85. South Korea Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 86. South Korea Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 87. South Korea Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 88. South Korea Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 89. Taiwan Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 90. Taiwan Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 91. Taiwan Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 92. Taiwan Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 93. Taiwan Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 94. Taiwan Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 95. Australia Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 96. Australia Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 97. Australia Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 98. Australia Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 99. Australia Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 100. Australia Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 101. Rest of Asia-Pacific Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 102. Rest of Asia-Pacific Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 103. Rest of Asia-Pacific Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 104. Rest of Asia-Pacific Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 105. Rest of Asia-Pacific Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 106. Rest of Asia-Pacific Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 107. Europe Anti-infective Agents, by Country USD Million (2017-2022)
  • Table 108. Europe Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 109. Europe Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 110. Europe Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 111. Europe Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 112. Europe Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 113. Europe Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 114. Germany Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 115. Germany Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 116. Germany Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 117. Germany Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 118. Germany Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 119. Germany Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 120. France Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 121. France Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 122. France Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 123. France Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 124. France Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 125. France Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 126. Italy Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 127. Italy Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 128. Italy Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 129. Italy Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 130. Italy Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 131. Italy Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 132. United Kingdom Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 133. United Kingdom Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 134. United Kingdom Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 135. United Kingdom Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 136. United Kingdom Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 137. United Kingdom Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 138. Netherlands Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 139. Netherlands Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 140. Netherlands Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 141. Netherlands Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 142. Netherlands Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 143. Netherlands Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 144. Rest of Europe Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 145. Rest of Europe Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 146. Rest of Europe Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 147. Rest of Europe Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 148. Rest of Europe Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 149. Rest of Europe Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 150. MEA Anti-infective Agents, by Country USD Million (2017-2022)
  • Table 151. MEA Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 152. MEA Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 153. MEA Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 154. MEA Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 155. MEA Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 156. MEA Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 157. Middle East Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 158. Middle East Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 159. Middle East Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 160. Middle East Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 161. Middle East Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 162. Middle East Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 163. Africa Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 164. Africa Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 165. Africa Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 166. Africa Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 167. Africa Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 168. Africa Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 169. North America Anti-infective Agents, by Country USD Million (2017-2022)
  • Table 170. North America Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 171. North America Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 172. North America Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 173. North America Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 174. North America Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 175. North America Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 176. United States Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 177. United States Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 178. United States Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 179. United States Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 180. United States Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 181. United States Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 182. Canada Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 183. Canada Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 184. Canada Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 185. Canada Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 186. Canada Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 187. Canada Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 188. Mexico Anti-infective Agents, by Type USD Million (2017-2022)
  • Table 189. Mexico Anti-infective Agents, by Application USD Million (2017-2022)
  • Table 190. Mexico Anti-infective Agents, by Drug Type USD Million (2017-2022)
  • Table 191. Mexico Anti-infective Agents, by Distribution Channel USD Million (2017-2022)
  • Table 192. Mexico Anti-infective Agents, by End-User USD Million (2017-2022)
  • Table 193. Mexico Anti-infective Agents, by Side Effects USD Million (2017-2022)
  • Table 194. Anti-infective Agents Sales: by Type(K Tons)
  • Table 195. Anti-infective Agents Sales Antibacterial Drugs , by Region K Tons (2017-2022)
  • Table 196. Anti-infective Agents Sales Antifungal Drugs , by Region K Tons (2017-2022)
  • Table 197. Anti-infective Agents Sales Antiviral Drugs , by Region K Tons (2017-2022)
  • Table 198. Anti-infective Agents Sales: by Application(K Tons)
  • Table 199. Anti-infective Agents Sales Hospital Use , by Region K Tons (2017-2022)
  • Table 200. Anti-infective Agents Sales Clinic Use , by Region K Tons (2017-2022)
  • Table 201. Anti-infective Agents Sales Household , by Region K Tons (2017-2022)
  • Table 202. Anti-infective Agents Sales Other , by Region K Tons (2017-2022)
  • Table 203. Anti-infective Agents Sales: by Drug Type(K Tons)
  • Table 204. Anti-infective Agents Sales Penicillins , by Region K Tons (2017-2022)
  • Table 205. Anti-infective Agents Sales Sulfonamides , by Region K Tons (2017-2022)
  • Table 206. Anti-infective Agents Sales Antimycobacterial , by Region K Tons (2017-2022)
  • Table 207. Anti-infective Agents Sales Trimethoprim-Sulfamethoxazole , by Region K Tons (2017-2022)
  • Table 208. Anti-infective Agents Sales Aminoglycosides , by Region K Tons (2017-2022)
  • Table 209. Anti-infective Agents Sales Macrolides , by Region K Tons (2017-2022)
  • Table 210. Anti-infective Agents Sales Chloramphenicol , by Region K Tons (2017-2022)
  • Table 211. Anti-infective Agents Sales Others , by Region K Tons (2017-2022)
  • Table 212. Anti-infective Agents Sales: by Distribution Channel(K Tons)
  • Table 213. Anti-infective Agents Sales Hospital Pharmacies , by Region K Tons (2017-2022)
  • Table 214. Anti-infective Agents Sales Retail Pharmacies , by Region K Tons (2017-2022)
  • Table 215. Anti-infective Agents Sales Online , by Region K Tons (2017-2022)
  • Table 216. Anti-infective Agents Sales Others , by Region K Tons (2017-2022)
  • Table 217. Anti-infective Agents Sales: by End-User(K Tons)
  • Table 218. Anti-infective Agents Sales Children , by Region K Tons (2017-2022)
  • Table 219. Anti-infective Agents Sales Adults , by Region K Tons (2017-2022)
  • Table 220. Anti-infective Agents Sales: by Side Effects(K Tons)
  • Table 221. Anti-infective Agents Sales Kidney Damage , by Region K Tons (2017-2022)
  • Table 222. Anti-infective Agents Sales GI Toxicity , by Region K Tons (2017-2022)
  • Table 223. Anti-infective Agents Sales Neurotoxicity , by Region K Tons (2017-2022)
  • Table 224. Anti-infective Agents Sales Hypersensitivity Reactions , by Region K Tons (2017-2022)
  • Table 225. Anti-infective Agents Sales Superinfections , by Region K Tons (2017-2022)
  • Table 226. South America Anti-infective Agents Sales, by Country K Tons (2017-2022)
  • Table 227. South America Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 228. South America Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 229. South America Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 230. South America Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 231. South America Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 232. South America Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 233. Brazil Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 234. Brazil Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 235. Brazil Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 236. Brazil Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 237. Brazil Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 238. Brazil Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 239. Argentina Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 240. Argentina Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 241. Argentina Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 242. Argentina Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 243. Argentina Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 244. Argentina Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 245. Rest of South America Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 246. Rest of South America Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 247. Rest of South America Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 248. Rest of South America Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 249. Rest of South America Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 250. Rest of South America Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 251. Asia Pacific Anti-infective Agents Sales, by Country K Tons (2017-2022)
  • Table 252. Asia Pacific Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 253. Asia Pacific Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 254. Asia Pacific Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 255. Asia Pacific Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 256. Asia Pacific Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 257. Asia Pacific Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 258. China Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 259. China Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 260. China Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 261. China Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 262. China Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 263. China Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 264. Japan Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 265. Japan Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 266. Japan Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 267. Japan Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 268. Japan Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 269. Japan Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 270. India Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 271. India Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 272. India Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 273. India Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 274. India Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 275. India Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 276. South Korea Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 277. South Korea Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 278. South Korea Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 279. South Korea Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 280. South Korea Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 281. South Korea Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 282. Taiwan Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 283. Taiwan Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 284. Taiwan Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 285. Taiwan Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 286. Taiwan Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 287. Taiwan Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 288. Australia Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 289. Australia Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 290. Australia Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 291. Australia Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 292. Australia Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 293. Australia Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 294. Rest of Asia-Pacific Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 295. Rest of Asia-Pacific Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 296. Rest of Asia-Pacific Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 297. Rest of Asia-Pacific Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 298. Rest of Asia-Pacific Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 299. Rest of Asia-Pacific Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 300. Europe Anti-infective Agents Sales, by Country K Tons (2017-2022)
  • Table 301. Europe Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 302. Europe Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 303. Europe Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 304. Europe Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 305. Europe Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 306. Europe Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 307. Germany Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 308. Germany Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 309. Germany Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 310. Germany Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 311. Germany Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 312. Germany Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 313. France Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 314. France Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 315. France Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 316. France Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 317. France Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 318. France Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 319. Italy Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 320. Italy Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 321. Italy Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 322. Italy Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 323. Italy Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 324. Italy Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 325. United Kingdom Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 326. United Kingdom Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 327. United Kingdom Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 328. United Kingdom Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 329. United Kingdom Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 330. United Kingdom Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 331. Netherlands Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 332. Netherlands Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 333. Netherlands Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 334. Netherlands Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 335. Netherlands Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 336. Netherlands Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 337. Rest of Europe Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 338. Rest of Europe Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 339. Rest of Europe Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 340. Rest of Europe Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 341. Rest of Europe Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 342. Rest of Europe Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 343. MEA Anti-infective Agents Sales, by Country K Tons (2017-2022)
  • Table 344. MEA Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 345. MEA Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 346. MEA Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 347. MEA Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 348. MEA Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 349. MEA Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 350. Middle East Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 351. Middle East Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 352. Middle East Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 353. Middle East Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 354. Middle East Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 355. Middle East Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 356. Africa Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 357. Africa Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 358. Africa Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 359. Africa Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 360. Africa Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 361. Africa Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 362. North America Anti-infective Agents Sales, by Country K Tons (2017-2022)
  • Table 363. North America Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 364. North America Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 365. North America Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 366. North America Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 367. North America Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 368. North America Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 369. United States Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 370. United States Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 371. United States Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 372. United States Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 373. United States Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 374. United States Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 375. Canada Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 376. Canada Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 377. Canada Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 378. Canada Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 379. Canada Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 380. Canada Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 381. Mexico Anti-infective Agents Sales, by Type K Tons (2017-2022)
  • Table 382. Mexico Anti-infective Agents Sales, by Application K Tons (2017-2022)
  • Table 383. Mexico Anti-infective Agents Sales, by Drug Type K Tons (2017-2022)
  • Table 384. Mexico Anti-infective Agents Sales, by Distribution Channel K Tons (2017-2022)
  • Table 385. Mexico Anti-infective Agents Sales, by End-User K Tons (2017-2022)
  • Table 386. Mexico Anti-infective Agents Sales, by Side Effects K Tons (2017-2022)
  • Table 387. Anti-infective Agents: by Type(USD/Units)
  • Table 388. Company Basic Information, Sales Area and Its Competitors
  • Table 389. Company Basic Information, Sales Area and Its Competitors
  • Table 390. Company Basic Information, Sales Area and Its Competitors
  • Table 391. Company Basic Information, Sales Area and Its Competitors
  • Table 392. Company Basic Information, Sales Area and Its Competitors
  • Table 393. Company Basic Information, Sales Area and Its Competitors
  • Table 394. Company Basic Information, Sales Area and Its Competitors
  • Table 395. Company Basic Information, Sales Area and Its Competitors
  • Table 396. Company Basic Information, Sales Area and Its Competitors
  • Table 397. Company Basic Information, Sales Area and Its Competitors
  • Table 398. Company Basic Information, Sales Area and Its Competitors
  • Table 399. Company Basic Information, Sales Area and Its Competitors
  • Table 400. Anti-infective Agents: by Type(USD Million)
  • Table 401. Anti-infective Agents Antibacterial Drugs , by Region USD Million (2023-2028)
  • Table 402. Anti-infective Agents Antifungal Drugs , by Region USD Million (2023-2028)
  • Table 403. Anti-infective Agents Antiviral Drugs , by Region USD Million (2023-2028)
  • Table 404. Anti-infective Agents: by Application(USD Million)
  • Table 405. Anti-infective Agents Hospital Use , by Region USD Million (2023-2028)
  • Table 406. Anti-infective Agents Clinic Use , by Region USD Million (2023-2028)
  • Table 407. Anti-infective Agents Household , by Region USD Million (2023-2028)
  • Table 408. Anti-infective Agents Other , by Region USD Million (2023-2028)
  • Table 409. Anti-infective Agents: by Drug Type(USD Million)
  • Table 410. Anti-infective Agents Penicillins , by Region USD Million (2023-2028)
  • Table 411. Anti-infective Agents Sulfonamides , by Region USD Million (2023-2028)
  • Table 412. Anti-infective Agents Antimycobacterial , by Region USD Million (2023-2028)
  • Table 413. Anti-infective Agents Trimethoprim-Sulfamethoxazole , by Region USD Million (2023-2028)
  • Table 414. Anti-infective Agents Aminoglycosides , by Region USD Million (2023-2028)
  • Table 415. Anti-infective Agents Macrolides , by Region USD Million (2023-2028)
  • Table 416. Anti-infective Agents Chloramphenicol , by Region USD Million (2023-2028)
  • Table 417. Anti-infective Agents Others , by Region USD Million (2023-2028)
  • Table 418. Anti-infective Agents: by Distribution Channel(USD Million)
  • Table 419. Anti-infective Agents Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 420. Anti-infective Agents Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 421. Anti-infective Agents Online , by Region USD Million (2023-2028)
  • Table 422. Anti-infective Agents Others , by Region USD Million (2023-2028)
  • Table 423. Anti-infective Agents: by End-User(USD Million)
  • Table 424. Anti-infective Agents Children , by Region USD Million (2023-2028)
  • Table 425. Anti-infective Agents Adults , by Region USD Million (2023-2028)
  • Table 426. Anti-infective Agents: by Side Effects(USD Million)
  • Table 427. Anti-infective Agents Kidney Damage , by Region USD Million (2023-2028)
  • Table 428. Anti-infective Agents GI Toxicity , by Region USD Million (2023-2028)
  • Table 429. Anti-infective Agents Neurotoxicity , by Region USD Million (2023-2028)
  • Table 430. Anti-infective Agents Hypersensitivity Reactions , by Region USD Million (2023-2028)
  • Table 431. Anti-infective Agents Superinfections , by Region USD Million (2023-2028)
  • Table 432. South America Anti-infective Agents, by Country USD Million (2023-2028)
  • Table 433. South America Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 434. South America Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 435. South America Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 436. South America Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 437. South America Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 438. South America Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 439. Brazil Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 440. Brazil Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 441. Brazil Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 442. Brazil Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 443. Brazil Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 444. Brazil Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 445. Argentina Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 446. Argentina Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 447. Argentina Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 448. Argentina Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 449. Argentina Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 450. Argentina Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 451. Rest of South America Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 452. Rest of South America Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 453. Rest of South America Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 454. Rest of South America Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 455. Rest of South America Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 456. Rest of South America Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 457. Asia Pacific Anti-infective Agents, by Country USD Million (2023-2028)
  • Table 458. Asia Pacific Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 459. Asia Pacific Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 460. Asia Pacific Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 461. Asia Pacific Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 462. Asia Pacific Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 463. Asia Pacific Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 464. China Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 465. China Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 466. China Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 467. China Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 468. China Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 469. China Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 470. Japan Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 471. Japan Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 472. Japan Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 473. Japan Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 474. Japan Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 475. Japan Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 476. India Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 477. India Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 478. India Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 479. India Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 480. India Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 481. India Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 482. South Korea Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 483. South Korea Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 484. South Korea Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 485. South Korea Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 486. South Korea Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 487. South Korea Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 488. Taiwan Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 489. Taiwan Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 490. Taiwan Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 491. Taiwan Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 492. Taiwan Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 493. Taiwan Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 494. Australia Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 495. Australia Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 496. Australia Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 497. Australia Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 498. Australia Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 499. Australia Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 500. Rest of Asia-Pacific Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 501. Rest of Asia-Pacific Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 502. Rest of Asia-Pacific Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 503. Rest of Asia-Pacific Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 504. Rest of Asia-Pacific Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 505. Rest of Asia-Pacific Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 506. Europe Anti-infective Agents, by Country USD Million (2023-2028)
  • Table 507. Europe Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 508. Europe Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 509. Europe Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 510. Europe Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 511. Europe Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 512. Europe Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 513. Germany Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 514. Germany Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 515. Germany Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 516. Germany Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 517. Germany Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 518. Germany Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 519. France Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 520. France Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 521. France Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 522. France Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 523. France Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 524. France Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 525. Italy Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 526. Italy Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 527. Italy Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 528. Italy Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 529. Italy Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 530. Italy Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 531. United Kingdom Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 532. United Kingdom Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 533. United Kingdom Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 534. United Kingdom Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 535. United Kingdom Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 536. United Kingdom Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 537. Netherlands Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 538. Netherlands Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 539. Netherlands Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 540. Netherlands Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 541. Netherlands Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 542. Netherlands Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 543. Rest of Europe Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 544. Rest of Europe Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 545. Rest of Europe Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 546. Rest of Europe Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 547. Rest of Europe Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 548. Rest of Europe Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 549. MEA Anti-infective Agents, by Country USD Million (2023-2028)
  • Table 550. MEA Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 551. MEA Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 552. MEA Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 553. MEA Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 554. MEA Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 555. MEA Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 556. Middle East Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 557. Middle East Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 558. Middle East Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 559. Middle East Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 560. Middle East Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 561. Middle East Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 562. Africa Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 563. Africa Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 564. Africa Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 565. Africa Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 566. Africa Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 567. Africa Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 568. North America Anti-infective Agents, by Country USD Million (2023-2028)
  • Table 569. North America Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 570. North America Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 571. North America Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 572. North America Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 573. North America Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 574. North America Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 575. United States Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 576. United States Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 577. United States Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 578. United States Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 579. United States Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 580. United States Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 581. Canada Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 582. Canada Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 583. Canada Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 584. Canada Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 585. Canada Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 586. Canada Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 587. Mexico Anti-infective Agents, by Type USD Million (2023-2028)
  • Table 588. Mexico Anti-infective Agents, by Application USD Million (2023-2028)
  • Table 589. Mexico Anti-infective Agents, by Drug Type USD Million (2023-2028)
  • Table 590. Mexico Anti-infective Agents, by Distribution Channel USD Million (2023-2028)
  • Table 591. Mexico Anti-infective Agents, by End-User USD Million (2023-2028)
  • Table 592. Mexico Anti-infective Agents, by Side Effects USD Million (2023-2028)
  • Table 593. Anti-infective Agents Sales: by Type(K Tons)
  • Table 594. Anti-infective Agents Sales Antibacterial Drugs , by Region K Tons (2023-2028)
  • Table 595. Anti-infective Agents Sales Antifungal Drugs , by Region K Tons (2023-2028)
  • Table 596. Anti-infective Agents Sales Antiviral Drugs , by Region K Tons (2023-2028)
  • Table 597. Anti-infective Agents Sales: by Application(K Tons)
  • Table 598. Anti-infective Agents Sales Hospital Use , by Region K Tons (2023-2028)
  • Table 599. Anti-infective Agents Sales Clinic Use , by Region K Tons (2023-2028)
  • Table 600. Anti-infective Agents Sales Household , by Region K Tons (2023-2028)
  • Table 601. Anti-infective Agents Sales Other , by Region K Tons (2023-2028)
  • Table 602. Anti-infective Agents Sales: by Drug Type(K Tons)
  • Table 603. Anti-infective Agents Sales Penicillins , by Region K Tons (2023-2028)
  • Table 604. Anti-infective Agents Sales Sulfonamides , by Region K Tons (2023-2028)
  • Table 605. Anti-infective Agents Sales Antimycobacterial , by Region K Tons (2023-2028)
  • Table 606. Anti-infective Agents Sales Trimethoprim-Sulfamethoxazole , by Region K Tons (2023-2028)
  • Table 607. Anti-infective Agents Sales Aminoglycosides , by Region K Tons (2023-2028)
  • Table 608. Anti-infective Agents Sales Macrolides , by Region K Tons (2023-2028)
  • Table 609. Anti-infective Agents Sales Chloramphenicol , by Region K Tons (2023-2028)
  • Table 610. Anti-infective Agents Sales Others , by Region K Tons (2023-2028)
  • Table 611. Anti-infective Agents Sales: by Distribution Channel(K Tons)
  • Table 612. Anti-infective Agents Sales Hospital Pharmacies , by Region K Tons (2023-2028)
  • Table 613. Anti-infective Agents Sales Retail Pharmacies , by Region K Tons (2023-2028)
  • Table 614. Anti-infective Agents Sales Online , by Region K Tons (2023-2028)
  • Table 615. Anti-infective Agents Sales Others , by Region K Tons (2023-2028)
  • Table 616. Anti-infective Agents Sales: by End-User(K Tons)
  • Table 617. Anti-infective Agents Sales Children , by Region K Tons (2023-2028)
  • Table 618. Anti-infective Agents Sales Adults , by Region K Tons (2023-2028)
  • Table 619. Anti-infective Agents Sales: by Side Effects(K Tons)
  • Table 620. Anti-infective Agents Sales Kidney Damage , by Region K Tons (2023-2028)
  • Table 621. Anti-infective Agents Sales GI Toxicity , by Region K Tons (2023-2028)
  • Table 622. Anti-infective Agents Sales Neurotoxicity , by Region K Tons (2023-2028)
  • Table 623. Anti-infective Agents Sales Hypersensitivity Reactions , by Region K Tons (2023-2028)
  • Table 624. Anti-infective Agents Sales Superinfections , by Region K Tons (2023-2028)
  • Table 625. South America Anti-infective Agents Sales, by Country K Tons (2023-2028)
  • Table 626. South America Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 627. South America Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 628. South America Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 629. South America Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 630. South America Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 631. South America Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 632. Brazil Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 633. Brazil Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 634. Brazil Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 635. Brazil Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 636. Brazil Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 637. Brazil Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 638. Argentina Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 639. Argentina Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 640. Argentina Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 641. Argentina Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 642. Argentina Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 643. Argentina Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 644. Rest of South America Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 645. Rest of South America Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 646. Rest of South America Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 647. Rest of South America Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 648. Rest of South America Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 649. Rest of South America Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 650. Asia Pacific Anti-infective Agents Sales, by Country K Tons (2023-2028)
  • Table 651. Asia Pacific Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 652. Asia Pacific Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 653. Asia Pacific Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 654. Asia Pacific Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 655. Asia Pacific Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 656. Asia Pacific Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 657. China Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 658. China Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 659. China Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 660. China Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 661. China Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 662. China Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 663. Japan Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 664. Japan Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 665. Japan Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 666. Japan Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 667. Japan Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 668. Japan Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 669. India Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 670. India Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 671. India Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 672. India Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 673. India Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 674. India Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 675. South Korea Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 676. South Korea Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 677. South Korea Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 678. South Korea Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 679. South Korea Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 680. South Korea Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 681. Taiwan Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 682. Taiwan Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 683. Taiwan Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 684. Taiwan Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 685. Taiwan Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 686. Taiwan Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 687. Australia Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 688. Australia Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 689. Australia Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 690. Australia Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 691. Australia Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 692. Australia Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 693. Rest of Asia-Pacific Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 694. Rest of Asia-Pacific Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 695. Rest of Asia-Pacific Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 696. Rest of Asia-Pacific Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 697. Rest of Asia-Pacific Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 698. Rest of Asia-Pacific Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 699. Europe Anti-infective Agents Sales, by Country K Tons (2023-2028)
  • Table 700. Europe Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 701. Europe Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 702. Europe Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 703. Europe Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 704. Europe Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 705. Europe Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 706. Germany Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 707. Germany Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 708. Germany Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 709. Germany Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 710. Germany Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 711. Germany Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 712. France Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 713. France Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 714. France Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 715. France Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 716. France Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 717. France Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 718. Italy Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 719. Italy Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 720. Italy Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
  • Table 721. Italy Anti-infective Agents Sales, by Distribution Channel K Tons (2023-2028)
  • Table 722. Italy Anti-infective Agents Sales, by End-User K Tons (2023-2028)
  • Table 723. Italy Anti-infective Agents Sales, by Side Effects K Tons (2023-2028)
  • Table 724. United Kingdom Anti-infective Agents Sales, by Type K Tons (2023-2028)
  • Table 725. United Kingdom Anti-infective Agents Sales, by Application K Tons (2023-2028)
  • Table 726. United Kingdom Anti-infective Agents Sales, by Drug Type K Tons (2023-2028)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-infective Agents: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-infective Agents: by Application USD Million (2017-2022)
  • Figure 6. Global Anti-infective Agents: by Drug Type USD Million (2017-2022)
  • Figure 7. Global Anti-infective Agents: by Distribution Channel USD Million (2017-2022)
  • Figure 8. Global Anti-infective Agents: by End-User USD Million (2017-2022)
  • Figure 9. Global Anti-infective Agents: by Side Effects USD Million (2017-2022)
  • Figure 10. South America Anti-infective Agents Share (%), by Country
  • Figure 11. Asia Pacific Anti-infective Agents Share (%), by Country
  • Figure 12. Europe Anti-infective Agents Share (%), by Country
  • Figure 13. MEA Anti-infective Agents Share (%), by Country
  • Figure 14. North America Anti-infective Agents Share (%), by Country
  • Figure 15. Global Anti-infective Agents: by Type K Tons (2017-2022)
  • Figure 16. Global Anti-infective Agents: by Application K Tons (2017-2022)
  • Figure 17. Global Anti-infective Agents: by Drug Type K Tons (2017-2022)
  • Figure 18. Global Anti-infective Agents: by Distribution Channel K Tons (2017-2022)
  • Figure 19. Global Anti-infective Agents: by End-User K Tons (2017-2022)
  • Figure 20. Global Anti-infective Agents: by Side Effects K Tons (2017-2022)
  • Figure 21. South America Anti-infective Agents Share (%), by Country
  • Figure 22. Asia Pacific Anti-infective Agents Share (%), by Country
  • Figure 23. Europe Anti-infective Agents Share (%), by Country
  • Figure 24. MEA Anti-infective Agents Share (%), by Country
  • Figure 25. North America Anti-infective Agents Share (%), by Country
  • Figure 26. Global Anti-infective Agents: by Type USD/Units (2017-2022)
  • Figure 27. Global Anti-infective Agents share by Players 2022 (%)
  • Figure 28. Global Anti-infective Agents share by Players (Top 3) 2022(%)
  • Figure 29. Global Anti-infective Agents share by Players (Top 5) 2022(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 37. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Gilead Sciences, Inc. (United States) Revenue: by Geography 2022
  • Figure 39. Bristol-Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bristol-Myers Squibb Co. (United States) Revenue: by Geography 2022
  • Figure 41. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 43. Bayer Healthcare AG (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Bayer Healthcare AG (Germany) Revenue: by Geography 2022
  • Figure 45. AstraZeneca Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. AstraZeneca Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 47. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Boehringer Ingelheim (Germany) Revenue: by Geography 2022
  • Figure 49. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 50. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 51. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 52. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2022
  • Figure 53. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 54. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 55. Global Anti-infective Agents: by Type USD Million (2023-2028)
  • Figure 56. Global Anti-infective Agents: by Application USD Million (2023-2028)
  • Figure 57. Global Anti-infective Agents: by Drug Type USD Million (2023-2028)
  • Figure 58. Global Anti-infective Agents: by Distribution Channel USD Million (2023-2028)
  • Figure 59. Global Anti-infective Agents: by End-User USD Million (2023-2028)
  • Figure 60. Global Anti-infective Agents: by Side Effects USD Million (2023-2028)
  • Figure 61. South America Anti-infective Agents Share (%), by Country
  • Figure 62. Asia Pacific Anti-infective Agents Share (%), by Country
  • Figure 63. Europe Anti-infective Agents Share (%), by Country
  • Figure 64. MEA Anti-infective Agents Share (%), by Country
  • Figure 65. North America Anti-infective Agents Share (%), by Country
  • Figure 66. Global Anti-infective Agents: by Type K Tons (2023-2028)
  • Figure 67. Global Anti-infective Agents: by Application K Tons (2023-2028)
  • Figure 68. Global Anti-infective Agents: by Drug Type K Tons (2023-2028)
  • Figure 69. Global Anti-infective Agents: by Distribution Channel K Tons (2023-2028)
  • Figure 70. Global Anti-infective Agents: by End-User K Tons (2023-2028)
  • Figure 71. Global Anti-infective Agents: by Side Effects K Tons (2023-2028)
  • Figure 72. South America Anti-infective Agents Share (%), by Country
  • Figure 73. Asia Pacific Anti-infective Agents Share (%), by Country
  • Figure 74. Europe Anti-infective Agents Share (%), by Country
  • Figure 75. MEA Anti-infective Agents Share (%), by Country
  • Figure 76. North America Anti-infective Agents Share (%), by Country
  • Figure 77. Global Anti-infective Agents: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Johnson & Johnson (United States)
  • Abbott Laboratories (United States)
  • Gilead Sciences, Inc. (United States)
  • Bristol-Myers Squibb Co. (United States)
  • Merck & Co., Inc. (United States)
  • Bayer Healthcare AG (Germany)
  • AstraZeneca Plc. (United Kingdom)
  • Boehringer Ingelheim (Germany)
  • Novartis AG (Switzerland)
  • Astellas Pharma, Inc. (Japan)
  • GlaxoSmithKline Plc. (United Kingdom)
Additional players considered in the study are as follows:
Alcon Pharmaceuticals Ltd. (Switzerland) , Sanofi-Aventis S.A. (France)
Select User Access Type

Key Highlights of Report


Jun 2023 244 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-infective Agents Quantitative research analysis
Global Anti-infective Agents Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Anti-infective Agents market are Pfizer Inc. (United States), Johnson & Johnson (United States), Abbott Laboratories (United States), Gilead Sciences, Inc. (United States), Bristol-Myers Squibb Co. (United States), Merck & Co., Inc. (United States), Bayer Healthcare AG (Germany), AstraZeneca Plc. (United Kingdom), Boehringer Ingelheim (Germany), Novartis AG (Switzerland), Astellas Pharma, Inc. (Japan) and GlaxoSmithKline Plc. (United Kingdom).
In this highly competitive & fast evolving Anti-infective Agents industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Hospital Use, Clinic Use, Household and Other are the potential customers of Anti-infective Agents industry.

Know More About Global Anti-infective Agents Report?

Have a Query? Click Here

Other Related Reports

Legal Marijuana Comprehensive Study by Type (Indoor, Greenhouse), Application (Chronic Pain, Mental Disorders, Cancer, Others), End-Users (Healthcare Industry, Recreational Industry, Others) Players ...
$ 3500
Veterinary Drugs Comprehensive Study by Type (Antibiotics, Non-Steroidal Anti-Inflammatories, Steroids, Opioid Pain Relievers, Anti-Parasitics, Behavior-Modifying Drugs and Sedatives, Hormones, Chemo...
$ 3750
Divalproex Sodium Comprehensive Study by Type (Tablet, Capsule, Others), Application (Epilepsy, Manic-Depressive Illness, Migraine Prophylaxis, Other), Sales Channel (Hospital Pharmacies, Online Phar...
$ 3450
Albumin Comprehensive Study by Type (Human Serum Albumin, Recombinant Albumin), Application (Drug Formulation, Vaccines, Medical Device Coating, Culture Medium & Stabilizer, Diagnostics, In Vitro Fer...
$ 3450
Acne Drugs Comprehensive Study by Mode of Administration (Oral, Topical, Injectable), Therapeutic Class (Retinoid, Antibiotic, Hormonal Agent, Combination, Others), Age Group (0-10 years, 11-16 years...
$ 3450
Hepatitis A Vaccine Comprehensive Study by Type (Liver Inactivated Vaccine, Live Attenuated Vaccine), Application (Hospitals & Clinics,, Others (Organizations Associated with Government Vaccinations ...
$ 3750